HISAMITSU PHARMACEUTICAL CO.,INC. Logo

HISAMITSU PHARMACEUTICAL CO.,INC.

A global leader in transdermal drug delivery systems for OTC and prescription pain relief.

4530 | T

Overview

Corporate Details

ISIN(s):
JP3784600003
LEI:
Country:
Japan
Address:
鳥栖市田代大官町408番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Hisamitsu Pharmaceutical Co., Inc. is a multinational pharmaceutical corporation engaged in the research, development, manufacture, and sale of prescription and over-the-counter (OTC) products. The company is a global leader in pain relief solutions, specializing in transdermal drug delivery systems. Its core portfolio features external analgesic and anti-inflammatory preparations, including well-known patches, plasters, and poultices. Hisamitsu actively pursues innovation in its field, with ongoing clinical research into next-generation technologies like microneedle drug delivery systems. Established in 1834, the company leverages its long history and expertise to market its therapeutic products worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 07:40
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 29.4 KB
2025-10-10 08:28
Registration Form
確認書
Japanese 9.2 KB
2025-10-10 08:25
Interim Report
半期報告書-第124期(2025/03/01-2026/02/28)
Japanese 240.4 KB
2025-10-03 08:43
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.7 KB
2025-09-03 08:36
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.0 KB
2025-08-05 08:45
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.1 KB
2025-05-23 08:00
Registration Form
確認書
Japanese 9.5 KB
2025-05-23 07:58
Governance Information
内部統制報告書-第123期(2024/03/01-2025/02/28)
Japanese 24.0 KB
2025-05-23 07:55
Registration Form
有価証券報告書-第123期(2024/03/01-2025/02/28)
Japanese 1.7 MB
2025-05-23 07:44
Post-Annual General Meeting Information
臨時報告書
Japanese 28.3 KB
2024-10-11 08:12
Registration Form
確認書
Japanese 9.2 KB
2024-10-11 08:08
Interim Report
半期報告書-第123期(2024/03/01-2025/02/28)
Japanese 244.4 KB
2024-07-12 08:12
Quarterly Report
確認書
Japanese 9.2 KB
2024-07-12 08:09
Quarterly Report
四半期報告書-第123期第1四半期(2024/03/01-2024/05/31)
Japanese 179.7 KB
2024-05-24 08:14
Registration Form
確認書
Japanese 9.5 KB

Automate Your Workflow. Get a real-time feed of all HISAMITSU PHARMACEUTICAL CO.,INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HISAMITSU PHARMACEUTICAL CO.,INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HISAMITSU PHARMACEUTICAL CO.,INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.